Cytokinetics, Incorporated

NASDAQ:CYTK

46.87 (USD) • At close January 15, 2025
Bedrijfsnaam Cytokinetics, Incorporated
Symbool CYTK
Munteenheid USD
Prijs 46.87
Beurswaarde 5,531,316,180
Dividendpercentage 0%
52-weken bereik 44.49 - 86.63
Industrie Biotechnology
Sector Healthcare
CEO Mr. Robert I. Blum
Website https://www.cytokinetics.com

An error occurred while fetching data.

Over Cytokinetics, Incorporated

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is

Vergelijkbare Aandelen

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

104.89 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

79.4 USD

CureVac N.V. logo

CureVac N.V.

CVAC

4.07 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

40.98 USD

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

9.71 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

101.53 USD

Karuna Therapeutics, Inc. logo

Karuna Therapeutics, Inc.

KRTX

329.83 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)